Vaccine Adjuvants Market - Segmented By Type, Mechanism of action (Active immunostimulants, Carriers, and Vehicle adjuvants), and Geography - Growth, Trends, and Forecast (2018 - 2023)
Report includes By Type (Mineral Salt Based Adjuvants, Tensoactive Adjuvants, Emulsions, Liposomes, Carbohydrates Adjuvants, Bacteria-Derived Adjuvants, Organic Adjuvants, Virus-Like Particles, And Others), By Mechanism of action (Active immunostimulants, Carriers, and Vehicle adjuvants), By Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America), and Forecast 2018 - 2023.
Vaccine Adjuvants Market Overview
Expanding government recommendations for immunizations, increasing technological innovations, unmet vaccine market needs for certain diseases, and increasing use of recombinant subunit and synthetic vaccines are the major factors contributing to the growth of the global vaccine adjuvants market which is expected to reach USD 1,036.40 million in 2023 at CAGR of x% from 2018 - 2023. Geographically, as of 2017, North America accounted for the highest market value and is expected to register an estimated CAGR of 8.37% during the forecast period. Moreover, Asia-Pacific is expected to record the highest CAGR of 9.22% during the forecast period. The increasing investments for R&D activities, production, and rising indigenous production are propelling the market in Asia-Pacific.
Expanding Government Recommendations for Immunizations Drives the Vaccine Adjuvants Market
Across the world, various governmental organizations are promoting and raising the awareness regarding immunization against various diseases, like anthrax, BCG, Hepatitis, HPV, Influenza, Varicella, Smallpox, and other conditions. The government spending on vaccination is a major thrust factor for development of new generation vaccines and adjuvants. Currently, CDC recommends routine vaccination, in order to prevent 17 vaccine-preventable diseases that occur in infants, children, adolescents, or adults. The Indian government also recommends a similar number of proteins to be administered to infants, in order to prevent various diseases, like polio, diphtheria, typhoid, and other conditions. All countries of the European Union have mandatory and recommended vaccination programs, along with various ways of implementing the national vaccination programs. This fact is fueling the global vaccination market’s growth. Moreover, most vaccines available recently are those used under government recommendations are being administered with an adjuvant. WHO launched the Global Adjuvant Development Initiative (GADI) to promote access to the public sector vaccine developers and manufacturers. WHO created AdjuNet a network to facilitate sharing of data gained with the adjuvants being developed by GADI, to minimize duplication of studies, and to ensure that vaccines developed using adjuvants provided by GADI are made available to developing countries at affordable prices. The world immunization profile has been mentioned in the graph below. These statistics state the effects of government initiatives in increasing immunization against various disease conditions, across the world. All of these factors are expected to propel the overall market for vaccine adjuvants over the forecast period.
Side Effects of Adjuvants Is Restricting the Growth of the Vaccine Adjuvants Market
Adjuvants have been used in human vaccines for over a century, yet, only very few adjuvants are licensed for use. The problem with these adjuvants used in modern day vaccines is the risk of adverse reactions, local or systemic. In addition, since each adjuvant generates a characteristic immune response, its applicability in many vaccines is limited. For example, the inability of alum-based adjuvants to induce Th1 antibody isotopes or cellular immune responses and the poor adjuvant effect on polysaccharide antigens limit their applicability in many vaccines. Few vaccine adjuvants trigger unwanted hyperactive immune responses, increasing the chance of loss of self-tolerance and the immune system attacking its own cells and tissues. Even if no serious adverse effects are observed in an extensive non-clinical toxicological and safety study, it may not be guaranteed that the new adjuvant formulation presents no risks to the patient, as unexpected events may occur. When considering vaccine development, the unacceptable side effects and toxicity preclude the use of many candidate adjuvants, as safety issues are paramount. To gain potency, minimizing toxicity is one of the major challenges in adjuvant development, which is hindering the expansion of the market.
Mineral Salt Based Adjuvants has the Largest Market Share
Mineral salt based adjuvants contribute 59.3% to the overall revenue generated from the segment by type in 2017. It was the most preferred adjuvant because of the fact that these adjuvants aids in increasing the efficiency of the vaccines, it is well tolerated and has potentially high IgG type antibodies. They are regularly used in diphtheria-tetanus-pertussis (DTP), polio, yellow fever, and BCG vaccines.
Vehicle adjuvants have Registered a High CAGR
Vehicle adjuvants are not immunogenic, and most vehicles can enhance antigens activity. Vehicle adjuvants like liposomes, immune stimulating complexes (ISCOMs), and micro/nanospheres play an important role in increasing the vaccine quality because of which they are expected to register a CAGR of 9.52%. Vehicle adjuvants are mostly used in developing vaccines for cancer, human immunodeficiency virus (HIV), or mucosal immune system
North America is anticipated to dominate the Vaccine Adjuvants Market
North America captured the largest market share in the global vaccine adjuvant market. The dominance of the region may be attributed to factors, such as higher adoption, greater knowledge about regular vaccination, and presence of major market players, coupled with higher healthcare expenditure. With growing prevalence of cancer and epidemic flu, a continuous investments in research is needed from the government, for which increased funding is received from the United States National Institutes of Health (NIH), FDA, and CDC.Consequently, with high funding, wide commercial availability of vaccines, awareness in society regarding vaccines contribute to the sustained growth in the United States at a CAGR of 7.99%.
Vaccine adjuvant developers are concentrating to provide technologically advanced products in order to serve mankind in a better way and to retain leading position in the market. For instance, Novavax reached significant milestone in the Preparing the phase III trial of its respiratory syncytial virus F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization in May 2018.
Major Players -Adjuvance, Adjuvatis, Brenntag AG, Chemtrade Logistics, GlaxoSmithKline, Invivogen, Merck KGaA, Novavax, Oz Biosciences, Seppic (Air Liquide), and Vaxliant.
Reasons to Purchase the Report
- Current and future of vaccine adjuvants market outlook in the developed and emerging markets
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support, along with the market estimate sheet (in Excel)
Customization of the Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs